{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:02:45Z","timestamp":1761490965034,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bcmd.2020.102420","type":"journal-article","created":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T06:25:43Z","timestamp":1583562343000},"page":"102420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms"],"prefix":"10.1016","volume":"82","author":[{"given":"Hakan","family":"Keski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcmd.2020.102420_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.bcmd.2020.102420_bb0010","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1152\/ajpendo.00056.2013","article-title":"Involvement of mast cells in adipose tissue fibrosis","volume":"306","author":"Hirai","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bcmd.2020.102420_bb0015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ki.2012.211","article-title":"Mast cell activation and degranulation promotes renal fibrosis in experimental unilateral ureteric obstruction","volume":"82","author":"Summers","year":"2012","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.bcmd.2020.102420_bb0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5858\/2005-129-219-EOMCIM","article-title":"Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes","volume":"129","author":"Dunphy","year":"2005","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"10.1016\/j.bcmd.2020.102420_bb0025","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.prp.2009.04.003","article-title":"Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study","volume":"205","author":"Ahmed","year":"2009","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bcmd.2020.102420_bb0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.humpath.2017.01.007","article-title":"Transforming growth factor beta- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow","volume":"62","author":"Nakayama","year":"2017","journal-title":"Hum. Pathol."},{"issue":"8","key":"10.1016\/j.bcmd.2020.102420_bb0035","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/gene.2010.35","article-title":"Mast cell homeostasis and the JAK-STAT pathway","volume":"11","author":"Morales","year":"2010","journal-title":"Genes Immun."},{"issue":"11","key":"10.1016\/j.bcmd.2020.102420_bb0040","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/cea.13217","article-title":"The JAK1\/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release","volume":"48","author":"Hermans","year":"2018","journal-title":"Clin. Exp. Allergy"},{"issue":"6","key":"10.1016\/j.bcmd.2020.102420_bb0045","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/stem.1661","article-title":"Concise review: evidence for CD34 as a common marker for diverse progenitors","volume":"32","author":"Sidney","year":"2014","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.bcmd.2020.102420_bb0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.2004.05280.x","article-title":"Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients","volume":"128","author":"Arora","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.bcmd.2020.102420_bb0055","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2004-08-3238","article-title":"Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases","volume":"105","author":"Xu","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcmd.2020.102420_bb0060","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s00277-016-2784-x","article-title":"Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study","volume":"95","author":"Orvain","year":"2016","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.bcmd.2020.102420_bb0065","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/10245332.2016.1232546","article-title":"Peripheral and bone marrow CD34(+) cell levels on chronic myeloproliferative disease","volume":"22","author":"Pamukcuoglu","year":"2017","journal-title":"Hematology"},{"issue":"11","key":"10.1016\/j.bcmd.2020.102420_bb0070","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcmd.2020.102420_bb0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bcmd.2020.102420_bb0080","first-page":"78","article-title":"Splenomegaly in 2,505 patients in a large university medical center from 1913 to 1995. 1913 to 1962: 2,056 patients","volume":"169","author":"O'Reilly","year":"1998","journal-title":"West J Med"},{"issue":"19","key":"10.1016\/j.bcmd.2020.102420_bb0085","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcmd.2020.102420_bb0090","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bcmd.2020.102420_bb0095","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bcmd.2020.102420_bb0100","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bcmd.2020.102420_bb0105","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcmd.2020.102420_bb0110","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/modpathol.2012.87","article-title":"The European consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis","volume":"25","author":"Gianelli","year":"2012","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.bcmd.2020.102420_bb0115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12032-014-0869-8","article-title":"Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis","volume":"31","author":"Lekovic","year":"2014","journal-title":"Med. Oncol."},{"issue":"11","key":"10.1016\/j.bcmd.2020.102420_bb0120","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.3109\/10428194.2013.769537","article-title":"Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis","volume":"54","author":"Nazha","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.bcmd.2020.102420_bb0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","article-title":"The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"Abdulkarim","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.bcmd.2020.102420_bb0130","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.bcmd.2020.102420_bb0135","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcmd.2020.102420_bb0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.stem.2013.08.009","article-title":"Sinister symbiosis: pathological hematopoietic-stromal interactions in CML","volume":"13","author":"Mullally","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.bcmd.2020.102420_bb0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.bcmd.2020.102420_bb0150","first-page":"1123","article-title":"Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders","volume":"88","author":"Passamonti","year":"2003","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.bcmd.2020.102420_bb0155","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","article-title":"Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia","volume":"98","author":"Barosi","year":"2001","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979619304772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979619304772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:35:40Z","timestamp":1761050140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979619304772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":31,"alternative-id":["S1079979619304772"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2020.102420","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2020.102420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102420"}}